Nivolumab (NCT07504796)

Name: Nivolumab trial for Metastatic Melanoma (NCT07504796)
Uploaded: 2026-10-31T21:43:39.368Z
Duration: 1 min 16 s
Description: Nivolumab trial for Metastatic Melanoma (NCT07504796). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07504796.

ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab: a one-minute explainerNCT075047961 min

Nivolumab trial for Metastatic Melanoma (NCT07504796). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults starting first-line treatment for unresectable or metastatic melanoma, excluding ocular melanoma. Tumor DNA must be detectable in blood at baseline.

The idea: nivolumab and relatlimab block immune brakes. After two doses, blood tests and scans guide whether ipilimumab is added. Patients with persistent tumor DNA but no early scan progression are randomized to continue or add ipilimumab; those with early progression add it. Researchers measure progression-free survival.

This phase 2 study plans 90 patients. Janice Mehnert leads at NYU Langone in New York, the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.